Investment
Features
FeesSafety
Academy
More
Pluang+

Compare New York Times Co (NYT) vs Twist Bioscience Corp (TWST) Price & Performance

New York Times CoTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

New York Times Co vs Twist Bioscience Corp — how do they compare? New York Times Co trades at $64.44 (market cap $10.28B), while Twist Bioscience Corp trades at $123.01 (market cap $7.72B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.44% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

NYTTWST
Market Cap
$10.28B$7.72B
Sector
MediaHealth
52-Week High
$85.86$124.88
52-Week Low
$54.66$24.16
Enterprise Value
$9.67B$7.65B
Dividend Yield
1.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

New York Times Co

The New York Times Company (NYT) trades at $64.80, up 1.98% today, with a bearish technical signal despite recent earnings beats. Fundamentals show strong revenue growth to $2.82 billion in 2025 and a net income margin of 13.19%, though digital subscriber growth concerns have pressured the stock. The current P/E ratio is 26.55, above industry averages, reflecting its premium valuation.

The outlook is mixed; solid profitability and a consensus price target of $77.50 suggest upside, but slowing subscriber additions and high valuation pose risks. Investor sentiment is cautious due to recent price weakness, with analysts predominantly holding a 'Hold' rating, indicating a wait-and-see approach for near-term catalysts.

Twist Bioscience Corp

TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.

The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.

Returns comparison

Trailing returns across standard periods

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST